Plus   Neg

Merck To Present New And Updated Data On KEYTRUDA, Updated Data On LYNPARZA

Merck (MRK) announced Thursday new and updated data from six abstracts investigating KEYTRUDA (pembrolizumab), the company's anti-PD-1 therapy, as both monotherapy and combination therapy, across a range of difficult-to-treat breast cancers.

The company will present these data at the 2017 San Antonio Breast Cancer Symposium or SABCS from December 5 - 9.

Further, updated data on LYNPARZA (olaparib), the first-in-class poly ADP-ribose polymerase or PARP inhibitor being co-developed and co-commercialized with AstraZeneca, will also be presented.

KEYTRUDA presentations include a Spotlight Session with findings from the phase 2 KEYNOTE-086 trial, Cohort B, investigating KEYTRUDA as a monotherapy in previously untreated patients with metastatic triple-negative breast cancer whose tumors express PD-L1.

Roy Baynes of Merck Research Laboratories said, "We have seen significant therapeutic advances over the years in the field of breast cancer; however, there remains significant unmet medical need, particularly in certain categories of the disease. Through our comprehensive clinical program studying KEYTRUDA, as well as LYNPARZA, we hope to bring additional therapeutic benefit to breast cancer patients."

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Treasury Secretary Steven Mnuchin announced Thursday he will not attend an investor conference in Saudi Arabia next week. Mnuchin revealed in a post on Twitter that he decided to drop out of the conference after meeting with President Donald Trump and Secretary of State Mike Pompeo. eBay Inc. has filed a lawsuit against Amazon.com Inc., accusing its e-commerce rival of illegally poaching sellers on its marketplace by infiltrating eBay's internal messaging system. The lawsuit filed by eBay on Wednesday in Santa Clara County in California, accuses Amazon of having "perpetrated a scheme to infiltrate and exploit eBay's internal member email system" over the past several years. Philip Morris International Inc. (PM) announced, for the third-quarter, reported and adjusted diluted earnings per share was $1.44, up 13.4% versus $1.27 in 2017. Excluding unfavorable currency of $0.09, adjusted diluted earnings per share up by 20.5% to $1.53 from $1.27 in 2017. On average, 13 analysts...
Follow RTT